Both are healing peptides. Both are frequently stacked. But they work differently — and understanding those differences determines which one your research actually needs.
Research context only. Neither compound is FDA-approved. This comparison is for educational purposes.
TB-500 and BPC-157 are the most researched healing peptides available and are frequently discussed together — sometimes even stacked together. But they work differently, have different evidence profiles, and suit different research objectives. Understanding the distinction is worth the effort.
| TB-500 | BPC-157 | |
|---|---|---|
| Source | Thymosin Beta-4 fragment | Gastric juice protein fragment |
| Primary mechanism | Actin / cell migration | Angiogenesis / growth factors / NO |
| Action radius | Systemic | Local (inject near injury) |
| Half-life | ~3–4 days | ~4 hours |
| Dosing frequency | 2x/week → 1x/week | Daily or 2x daily |
| Best tissue | Tendons, systemic | Gut, tendons, ligaments, nerves |
| Gut healing | Limited data | Strong evidence |
| WADA status | Prohibited | Not currently listed |
TB-500 works primarily through actin regulation and cell migration. It binds G-actin, facilitating the movement of repair cells to damaged tissue — and it does this systemically, circulating throughout the body and finding areas that need repair. It also drives VEGF-mediated angiogenesis and suppresses inflammatory cytokines.
BPC-157 works through a distinct set of pathways: it upregulates growth factors (including EGF and FGF), modulates nitric oxide signaling (which drives vascular repair), and has demonstrated direct effects on tendon-to-bone healing and gut mucosal repair. Its effects are most potent when delivered near the target tissue.
Why they stack: The mechanisms genuinely complement each other. TB-500 handles systemic repair coordination and cell recruitment; BPC-157 handles local tissue repair and growth factor signaling. Using both simultaneously covers more of the healing cascade than either alone — which is why the Injury Stack bundle exists.
| Scenario | Better Choice | Why |
|---|---|---|
| Tendon / ligament injury | Both (stack) | Complementary mechanisms; most researched combination |
| Gut / GI healing | BPC-157 | Strongest gut evidence base; oral route viable for GI targeting |
| Systemic inflammation | TB-500 | Systemic anti-inflammatory action; doesn't need local injection |
| Muscle tear | Both (stack) | TB-500 for satellite cell recruitment; BPC-157 for local repair |
| Nerve damage | BPC-157 | Better neuroprotective evidence |
| Convenience (infrequent dosing) | TB-500 | Weekly dosing vs BPC-157's daily requirement |
| Competitive athletes | BPC-157 | TB-500 is WADA prohibited; BPC-157 is not currently listed |
They're not competing compounds — they're complementary ones. The most common research protocol uses both together. If forced to choose one, the decision comes down to your specific research objective: gut/nerve/localized healing favors BPC-157; systemic, hard-to-target, or systemic inflammation scenarios favor TB-500. WADA status is a real differentiator for tested athletes.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage CalculatorCOA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator